Review of the Unique Properties of Budesonide

Clinical Therapeutics

Volumn 25, Issue SUPPL. C, 2003, Pages

  O'Connell, Edward J ^a  

^a MAYO CLINIC   (United States)

Author keywords

Airway selectivity; Budesonide; Efficacy; Safety

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; GLUCOCORTICOID; MOMETASONE FUROATE; PREDNISOLONE; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ASTHMA; CATARACT; CHILD; CLINICAL TRIAL; COUGHING; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG RETENTION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY POWDER; ESTERIFICATION; GROWTH RETARDATION; HOARSENESS; HUMAN; INTRAOCULAR HYPERTENSION; LIPOPHILICITY; METERED DOSE INHALER; NEBULIZATION; PHYSICAL CHEMISTRY; POWDER INHALER; REVIEW; SORE THROAT;

EID: 0242629020     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80305-3     Document Type: Article

References (96)

1. Pahl A, Szelenyi I. Asthma therapy in the new millennium. Inflamm Res. 2002;51: 273-282.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1995. Publication 95-3659.
3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002. Publication 02-3659.
4. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, Md: National Institutes of Health; 1997. Publication 97-4051.
5. Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention. Bethesda, Md: National Institutes of Health; 1998. Publication 96-3659B.
6. Barnes PJ, Adcock I. Anti-inflammatory actions of steroids: Molecular mechanisms. Trends Pharmacol Sci. 1993;14:436-441.
7. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther. 2002;15:35-50.
8. Edsbäcker S. Pharmacological factors that influence the choice of inhaled corticosteroids. Drugs. 1999;58:7-16.
9. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: Part 1. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol. 1998;102:S36-S51.
10. Brown HM, Storey G, George WH. Beclomethasone dipropionate: A new steroid aerosol for the treatment of allergic asthma. BMJ. 1972;1:585-590.
11. Brattsand R, Axelsson BI. Basis of airway selectivity of inhaled glucocorticoids. In: Schleimer RP, Busse WW, O'Byrne PM, eds. Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Dekker; 1997:351-379.
12. Brattsand R. Drug development of inhaled steroids: A pharmacologist's view based upon experiences from the budesonide project. In: Schleimer R, O'Byrne P, Szefler S, Brattsand R, eds. Inhaled Steroids in Asthma: Optimizing Effects in the Airways. New York: Dekker; 2002:3-33.
13. Phillipps GH. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate. Respir Med. 1990;84(Suppl A):19-23.
14. Brattsand R, Axelsson BI. New inhaled glucocorticosteroids. New Drugs for Asthma. 1992;2:193-208.
15. Brattsand R, Thalén A, Roempke K, et al. Influence of 16α, 17α-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids. J Steroid Biochem. 1982;16:779-786.
16. Affrime MB, Cuss F, Padhi D, et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J Clin Pharmacol. 2000;40:1227-1236.
17. Andersson N, Klint S, Randwall G, Wirén J-E. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay. Am J Respir Crit Care Med. 1994;149: A467. Abstract.
18. Brattsand R. Development of glucocorticosteroids with lung selectivity. In: Hargreaves FE, Hogg JC, Malo JL, Toogood JH, eds. Glucocorticoids and Mechanisms of Asthma. Amsterdam, the Netherlands: Excerpta Medica; 1989:17-38.
19. Brattsand R, Ingelf J. Pharmacodynamic and pharmacokinetic basis for inhaled glucocorticosteroid (GCS) therapy in allergic rhinitis. In: Melillo G, O'Byrne PM, Marone G, eds. Respiratory Allergy: Advances in Clinical Immunology and Pulmonary Medicine. Proceedings of the 3rd International Meeting on Respiratory Allergy, Naples, 1-4 April 1992. Amsterdam, the Netherlands: Excerpta Medica; 1993:129-136.
20. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler™ is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994;7:1839-1844.
21. Thorsson L, Dahlström K, Edsbäcker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol. 1997;43: 155-161.
22. Brattsand R. What factors determine anti-inflammatory activity and selectivity of inhaled steroids? Eur Respir Rev. 1997;7:356-361.
23. Edsbäcker S, Szefler SJ. Glucocorticoid pharmacokinetics: Principles and clinical applications. In: Schleimer RP, Busse WW, O'Byrne PM, eds. Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Dekker; 1997:381-445.
24. Harding SM. The human pharmacology of fluticasone propionate. Respir Med. 1990;84(Suppl A):25-29.
25. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy. 1997;52(Suppl 39):1-34.
26. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol. 1998;101:S440-S446.
27. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998;26:623-630.
28. Wieslander EI, Delander EL, Järkelid L, et al. Pharmacological importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line in vitro. Am J Respir Cell Mol Biol. 1998;19:477-484.
29. Thorsson L, Thunnisen FB, Korn S, et al. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo. Am J Respir Crit Care Med. 1998;157:A404. Abstract.
30. Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos. 1997;25:1311-1317.
31. Jendbro M, Johansson CJ, Strandberg P, et al. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos. 2001;29:769-776.
32. Edsbäcker S, Brattsand R. Budesonide fatty-acid esterification: A novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol. 2002;88:609-616.
33. Miller-Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med. 2000;162:1455-1461.
34. Miyamoto T, Takahashi T, Nakajima S, et al. A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler study group. Respirology. 2000;5:247-256.
35. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma [published erratum appears in J Allergy Clin Immunol. 1998;102:511]. J Allergy Clin Immunol. 1998;101:457-463.
36. Shapiro G, Bronsky EA, LaForce CF, et al. Dose-related efficacy of budesonide administered via a dry powder inhaler in the treatment of children with moderate to severe persistent asthma. J Pediatr. 1998;132:976-982.
37. Lipworth BJ. Airway and systemic effects of inhaled corticosteroids in asthma: Dose response relationship. Pulm Pharmacol. 1996;9:19-27.
38. Bloom BS. Daily regimen and compliance with treatment. BMJ. 2001;323:647.
39. Campbell LM, Watson DG, Venables TL, et al. Once daily budesonide Turbohaler compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res. 1991;2:111-122.
40. Campbell LM, Gunn SD, Sweeney D, et al. Once daily budesonide: Effective control of moderately severe asthma with 800 μg once daily inhaled via Turbohaler when compared with 400 μg twice daily. Eur J Clin Res. 1995;7:1-14.
41. Jones AH, Langdon CG, Lee PS, et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med. 1994;88:293-299.
42. McFadden ER, Casale TB, Edwards TB, et al. Administration of budesonide once daily by means of Turbuhaler to subjects with stable asthma. J Allergy Clin Immunol. 1999; 104:46-52.
43. Campbell LM, Bodalia B, Gogbashian CA, et al. Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. PETITE Research Group. Int J Clin Pract. 1998;52:213-219.
44. Möller C, Strömberg L, Oldaeus G, et al. Efficacy of once-daily versus twice-daily administration of budesonide by Turbuhaler® in children with stable asthma. Pediatr Pulmonol. 1999;28:337-343.
45. Shapiro GG, Mendelson LM, Pearlman DS. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. Ann Allergy Asthma Immunol. 2001; 86:633-640.
46. Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103:414-421.
47. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999;83:231-239.
48. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J. 1999;14: 1038-1043.
49. Casale TB, Nelson HS, Kemp J, et al. Budesonide Turbuhaler delivered once daily improves health-related quality of life and maintains improvements with a stepped-down dose in adults with mild to moderate asthma. Ann Allergy Asthma Immunol. 2003;90:323-330.
50. Metzger WJ, Hampel FC Jr, Sugar M. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) is effective and safe in adults previously treated with inhaled corticosteroids. J Asthma. 2002;39:65-75.
51. Szefler S, Eigen H. Budesonide inhalation suspension: A nebulized corticosteroid for persistent asthma. J Allergy Clin Immunol. 2002;109:730-742.
52. Godfrey S, Avital A, Rosier A, et al. Nebulised budesonide in severe infantile asthma. Lancet. 1987;2:851-852.
53. Ilangovan P, Pedersen S, Godfrey S, et al. Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension. Arch Dis Child. 1993;68: 356-359.
54. de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study. J Allergy Clin Immunol. 1996;98:14-20.
55. Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998;102:789-796.
56. White MV, Cruz-Rivera M, Walton-Bowen K. The efficacy and safety of budesonide inhalation suspension: A nebulizable corticosteroid for persistent asthma in infants and young children. Fam Med. 1999;31:337-345.
57. Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999;88:835-840.
58. Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr. 1999;88:841-843.
59. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. Bethesda, Md: National Institutes of Health; 2002. Publication 02-5075.
60. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication. Clin Immunother. 1996;6:273-299.
61. Borgström L, Derom E, Ståhl E, et al. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med. 1996;153: 1636-1640.
62. Borgström L, Asking L, Beckman O, et al. Dose variation, within and between individuals, with different inhalation systems. Proceedings of Respiratory Drug Delivery V. Phoenix, April 28-May 2, 1996. Buffalo Grove: Interpharm Press; 1996:19-24.
63. Borgström L, Bengtsson T, Derom E, Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm. 2000;193:227-230.
64. Olsson B. Aerosol particle generation from dry powder inhalers: Can they equal pressurized metered dose inhalers? J Aerosol Med. 1995;8(Suppl 3):S13-S19.
65. Clark A. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. In: Dalby R, Byron P, Farr S, eds. Respiratory Drug Delivery. IV ed. Buffalo Grove: Interpharm Press; 1994:117-123.
66. Brown PH, Ning AC, Greening AP, et al. Peak inspiratory flow through Turbuhaler in acute asthma. Eur Respir J. 1995;8:1940-1941.
67. Ståhl E, Ribeiro LB, Sandahl G. Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler® in children with mild to moderate asthma. Pediatr Pulmonol. 1996;22:106-110.
68. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr. 1998;157:1017-1022.
69. Engel T, Heinig JH, Malling HJ, et al. Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler. Allergy. 1989;44:220-225.
70. Selroos O, Backman R, Forsén K-O, et al. Local side-effects during 4-year treatment with inhaled corticosteroids - a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy. 1994;49:888-890.
71. Katsunma T, Akasawa A, Iikura Y. Adrenal function of children with bronchial asthma treated with beclomethasone dipropionate. Ann Allergy. 1992;69:529-532.
72. Gagnon M, Cote J, Milot J, et al. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest. 1994;105: 1732-1737.
73. Aaronson D, Kaiser H, Dockhorn R, et al. Effects of budesonide by means of the Turbuhaler on the hypothalamic-pituitary-adrenal axis in asthmatic subjects: A dose-response study. J Allergy Clin Immunol. 1998;101:312-319.
74. Fitzgerald D, Van Asperen P, Mellis C, et al. Fluticasone propionate 750 micrograms/ day versus beclomethasone dipropionate 1500 micrograms/day: Comparison of efficacy and adrenal function in paediatric asthma. Thorax. 1998;53:656-661.
75. Allen DB. Limitations of short-term studies in predicting long-term adverse effects of inhaled corticosteroids. Allergy. 1999;54(Suppl 49):29-34.
76. Chrousos GP, Harris AG. Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Neuroimmunomodulation. 1998;5: 277-287.
77. Irani AM, Cruz-Rivera M, Fitzpatrick S, et al. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol. 2002;88:306-312.
78. Kemp J, and the Pulmonary and Turbuhaler Study Group. Long-term safety and efficacy of Pulmicort (budesonide) Turbuhaler in asthma. Abstract presented at: Annual Meeting of the American Academy of Allergy and Immunology (AAAI) and the American Thoracic Society (ATS), ATS Conference on Asthma; July 15-17, 1995; Chicago, Ill.
79. Ribeiro LB. A 12 month tolerance study with budesonide in asthmatic children. Paper presented at: 13th Congress of the European Academy of Allergology and Clinical Immunity, Corticosteroids in Childhood Asthma; May 6, 1986; Budapest, Hungary.
80. Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: A dose response study. Eur Respir J. 1997;10:1507-1512.
81. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: A meta-analysis. Pediatrics. 2000;106:E8.
82. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069.
83. Long-term effects of budesonide or nedocromil in children with asthma. Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343:1054-1063.
84. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med. 1998;157:178-183.
85. Tattersfield AE, Town GI, Johnell O, et al. Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax. 2001;56:272-278.
86. Pauwels RA, Löfdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med. 1999;340:1948-1953.
87. Jones A, Fay JK, Burr M, et al. Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;1:CD003537.
88. Sharma PK, Malhotra S, Pandhi P, Kumar N. Effect of inhaled steroids on bone mineral density: A meta-analysis. J Clin Pharmacol. 2003;43:193-197.
89. Duh MS, Walker AM, Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. Ann Allergy Asthma Immunol. 2000;85:356-361.
90. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14.
91. Garbe E, Suissa S, LeLorier J. Assocation of inhaled corticosteroid use with cataract extraction in elderly patients [published erratum appears in JAMA. 1998;280:1830]. JAMA. 1998;280:539-543.
92. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology. 2001;12:229-234.
93. Agertoft L, Larsen FE, Pedersen S. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Eur Respir J. 1998;12:130-135.
94. Källén B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol. 1999;93:392-395.
95. Norjavaara E, de Verdier M. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003;111:736-742.
96. Skoner DP. Therapeutic margin of budesonide in patients with mild to severe asthma. Clin Ther. 2003;25(Suppl C):C61-C74.